neo_oropharyngeal
oropharyngeal cancer
introduction
- 0.7% of men will develop oropharyngeal cancer (prior to widespread HPV vaccination)
- there appears to be 2 distinct groups of oropharyngeal cancer:
- HPV infection (mainly HPV type 16) related:
- now accounts for ~70% of oropharyngeal cancers
- has the better 5 year survival rate (75-80% for stage III/IV), and accounts for over 60% of the tumours
- expression of viral E6 and E7 oncoproteins that inactivate tumour suppressor proteins p53 and retinoblastoma protein (pRb), respectively, is necessary for malignant behaviour of these tumours
- tobacco-related carcinogens may render HPV-positive tumours less responsive to Rx
- ~7% of the adult population have oral HPV 1)
- 10% of men and ~4% of women have it
- risk of oral HPV (prior to widespread HPV vaccination) 2):
- 15% of men if smoke and 5 or more oral sex partners
- 7.4% of men who do not smoker but had 5 or more oral sex partners
- 7.1% of men if smoke and 2-4 oral sex partners
- 4% of men who do not smoker but had 2-4 oral sex partners
- 1.5% of men who had less than 2 oral sex partners
- 1.8% of female smokers who had less than 2 oral sex partners
- 0.5% of female non-smokers who had less than 2 oral sex partners
- 1% of the adult population have oral HPV type 16 which is associated with over 90% of oropharyngeal squamous cell carcinomas
- it appears oral HPV infection is predominantly sexually transmitted
- current smoking and intensity of smoking were independently associated with oral HPV infection, particularly among women
- peak ages for oral HPV infection were 30–34 years and 60–64 years. This bimodal age pattern was particularly striking among men.
- the number of HPV-positive oropharyngeal cancers diagnosed each year will surpass that of invasive cervical cancers by the year 2020
- HPV-positive oropharyngeal tumours were increasing in incidence, now exceeding the number of these tumours caused by tobacco and alcohol abuse
- hpv-negative, alcohol or cigarette related tumours:
- 5 year survival rate 45-50% for stage III/IV3)
- a 2013 study showed 55% patients with HPV-positive cancers were alive two years after a recurrence, compared with 28% of those with HPV-negative cancers
neo_oropharyngeal.txt · Last modified: 2017/10/21 22:16 by 127.0.0.1